Anand Mehra's Insider Trades & SAST Disclosures
Anand Mehra's most recent trade in Merus N.V was a trade of 13,193 Share Option (right to buy) done . Disclosure was reported to the exchange on May 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Anand Mehra.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Merus N.V | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 13,193 | 13,193 | - | - | Share Option (right to buy) | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 19 Nov 2024 | 666,666 | 710,030 (1%) | 1% | 2.3 | 1,499,999 | Common Stock |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 4,793 | 4,793 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 43,364 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 0 | - | - | Restricted Stock Units | |
| Merus N.V | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 8,844 | 8,844 | - | - | Share Option (right to buy) | |
| Merus N.V | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 14,414 | 14,414 | - | - | Share option (right to buy) | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,660 | 4,660 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 38,704 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,507 | 4,507 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 34,197 (0%) | 0% | - | Common Stock | |
| Merus N.V | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 16,604 | 16,604 | - | - | Share option (right to buy) | |
| Merus N.V | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 6,120 | 6,120 | - | - | Share option (right to buy) | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 8,000 | 0 | - | - | Option Grant (right to buy) | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.35 per share. | 02 Feb 2021 | 8,000 | 24,209 (0%) | 0% | 18.4 | 146,800 | Common Stock |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2021 | 6,632 | 0 | - | - | Option Grant (right to buy) | |
| Aclaris Therapeutics Inc | Anand Mehra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.32 per share. | 02 Feb 2021 | 6,632 | 30,841 (0%) | 0% | 18.3 | 121,498 | Common Stock |
| Merus N.V | Anand Mehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 8,631 | 8,631 | - | - | Share Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges